Company announcement, Inside information, Helsinki 15 October 2019 at 1.50 PM (EEST)

Changes in the Nexstim Plcs Board

Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") the company developing and marketing a unique brain stimulation technology for personalized treatment of major depressive disorder (MDD), announces changes in its Board composition.

Following the meeting of the Nomination Committee, Ken Charhut and Juliet Thompson, members of the Board of Directors since 2013 and 2015 respectively, have resigned their positions. The Company will later today release a new Company Announcement convening an Extraordinary General Meeting of Shareholders which will include the election of new members to the Board of Directors.

Martin Jamieson, Chairman and CEO of Nexstim, commented: We thank Ken Charhut and Juliet Thompson for their long-standing work on the Nexstim Board and its committees. We wish them all the best in the future. The EGM announcement will provide further details of this planned restructure of the Nexstim Board.

Further information is available on the website http://www.nexstim.com, or by contacting:

Martin Jamieson, Chairman and CEO+44 771 516 3942martin.jamieson@nexstim.com

Sisu Partners Oy (Certified Adviser)Jussi Majamaa+ 358 40 842 4479jussi.majamaa@sisupartners.com

About Nexstim Plc

Nexstim is a Finnish, globally operating medical technology company. Our mission is to enable personalized and effective therapies and diagnostics for challenging brain diseases and disorders.

Nexstim has developed a world-leading non-invasive brain stimulation technology called SmartFocus. It is a navigated transcranial magnetic stimulation (nTMS) technology with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.

SmartFocus technology is used in Nexstims proprietary Navigated Brain Therapy (NBT) system, which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBT system is CE marked for the treatment of major depression and chronic neuropathic pain.

In addition, Nexstim is commercializing its SmartFocus based Navigated Brain Stimulation (NBS) system for diagnostic applications. The NBS system is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain. Nexstim shares are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.

For more information please visitwww.nexstim.com

Attachment

Read the rest here:

Changes in the Nexstim Plcs Board - Yahoo Finance

LAREDO, Texas, Oct. 14, 2019 (GLOBE NEWSWIRE) -- Fr8Hub co-founder and CEO Ohad Axelrod will join the list of notable speakers at Journal of Commerces Inland Distribution conference, held Oct. 21-23 in Chicago. Axelrod will be part of the US-Mexico Cross-Border Trade: Threading the Needle session, held on Oct. 23 at 1:45 CT at theMarriott Marquis Chicago.Axelrod discussed the current cross-shipping environment with session moderator Bill Cassidy in a recent Journal of Commerce article, Lack of visibility delays US-Mexico truck freight:Infrastructure is a pain point, said Axelrod. You look at the roads leading to the border from Monterrey, and some of these sections are pretty horrible to drive. The more freight is moved, the worse the situation is likely to get.Were bridging the gap to build relationships between carriers in the United States and carriers like TMS in Mexico, to simplify the process of cross-border shipping, said Axelrod.Last week, Fr8Hub announced a partnership with Transportes Monroy Schiavon (TMS), one of the leading asset-based carriers in Mexico for more than 40 years. TMS extensive trucking fleet will immediately become part of Fr8Hubs carrier network, making their fleet of trucks available to match with shippers loads throughout Mexico.Fr8Hub combines extensive logistics experience with innovative cloud-based technology that directly matches shippers and freight forwarders in the U.S. and Mexico with a broad network of reliable carriers. Fr8Hub provides flexibility, visibility and simplicity for the once-complex process of international over-the-road (OTR) shipping. Fr8Hubs digital freight marketplace is integrated with fleet and driver IOT devices to synthesize and analyze together large amounts of data on each fleet and shipment, including location, freight, time and other data points. Shippers and carriers can access this critical data through the Fr8Hub Control Center to make timely, actionable decisions on loads, optimize their operations and reduce costs.The JOC Inland Distribution Conference serves shippers and transportation providers who move goods within North America and from North American ports to the inland destination. To learn more about Fr8Hub, please visit http://www.fr8hub.com. Media Contact: Will HarawayBackbeat Marketing404.593.8320william@backbeatmarketing.comwww.linkedin.com/in/willharawaywww.backbeatmarketing.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/2128fd7e-4f96-447b-b151-1d5e3c75b250

Continue reading here:

Fr8Hub CEO Ohad Axelrod to Discuss US-Mexico Cross-Border Trade at Journal of Commerce Inland Conference - Yahoo Finance

As you can see, The Mary Sue has a gorgeous new look. Heres what you can expect from our updated design.

The Mary Sue community as you know it wont be changingour excellent and incisive commenters can be found after the article as ever. Our article pages now are widerand lovely to read, and youll have an easier time finding related stories to keep reading on your favorite topics. Everything looks splendid on mobile, as well, if we do say so ourselves.

The chronological scroll our community prefers remains in place, as does the comment count on every article so that you can quickly see where discussion is happening. We know that change on the internet can feel tricky to navigate, so we tried to preserve all the things we love best about how The Mary Sue works while plotting her upgrade for the future.

Now youll be able to quickly focus in on the most popular articles on site, and well also be curating selections of our favorite TMS posts for your reading pleasure under Our Picks. We have more space to feature videos and art, which we cant wait to share with you.

We also have a rainbow-colored Breaking News bar that well use when big things are going downso keep your eyes peeled up top for what weve nicknamed the Bifrost Bar.

Questions? Comments? We know youll have em! Were excited to welcome you to the new Mary Sue.

(images: Marvel Studios, Marvel Comics)

Want more stories like this? Become a subscriber and support the site!

The Mary Sue has a strict comment policy that forbids, but is not limited to, personal insults toward anyone, hate speech, and trolling.

Have a tip we should know? tips@themarysue.com

Go here to see the original:

Welcome to the Shiny New Mary Sue - The Mary Sue

07/09/2018 - Important announcement - Investing in our team - TMS - your partner in business

We are delighted to tell you that the team at TMS Motor Spares have taken the decision to become part of Alliance Automotive Group.This enhancement is being carried out with our customers in mind.. You will still speak and see all the team that youve worked with through the years.. We will invest in the business, adding to our team, stocking the leading brands and enhancing the range and quantity of stock held.. We will increase the number of delivery vans as we build the business. All these investments will ensure you will continue to receive the very best service that TMS have been famous for.A solid foundationAlliance Automotive is a leading distributor of automotive and commercial vehicle parts and accessories, supplying car parts and accessories across Europe. With one of the largest centralised purchasing structures in the UK, we can fulfil orders speedily, with knowledge and accuracy and within a competitive pricing structure.In the coming weeks there will be a few changes in supplier brands including the introduction of more original equipment quality suppliers, this will include Bosch, Delphi, Delco Remy, LUK and OE engine management products.

This web site will be updated in due course with all the relevant information including supplier updates and value added services the Alliance Automotive Group & Group Auto have to offer.

Thank you for your custom and long may it continue.

Kind regards, TMS Motor Spares

Follow this link:

TMS Motor Spares Ltd

TMS is a Terminal Management System being used at our marine terminals - ITS Long Beach CA, and Husky Tacoma WA. TMS provides a direct access to your choice of terminal's data such as;

Click Sign Up link located at the top right corner of this screen, and follow the instruction. Sign-up is free and takes just a few minites to complete. To complete sign-up, you will need one recent (approximately within the last 90 days) B/L or Booking number for each shipping line you want to have access. This is necessary for us to verify that you have legitimate business with those shipping lines. Once you have successfully completed sign-up, you will receive the confirmation email that informs your TMS User Name for log-in.

No, you don't. Your TMS User Name will allow you to log in all terminals you select during sign-up process. After log-in, you can update your profile later at anytime to add or remove terminal access by clicking My Account link located at the top right corner. My Account page will also allow you to add more shipping lines to access as you need.

[ ITS Long Beach ] International Transportation Service, Inc. 1281 Pier G Way, Long Beach, CA 90802-6353

[ Husky Tacoma ] Husky Terminal & Stevedoring, Inc. 1101 Port of Tacoma Road Terminal Four, Tacoma, WA 98421-3701

Read more from the original source:

TMS - Welcome to TMS

TMS - Wholesale TMS Wholesale

Welcome to a totally different kind of mortgage lender. At TMS, we speak a different language, we do business in a different way. And everything we do revolves around a single mission: to Grow Happiness. With us, youll know things like Joyitude, the unexpected adjustment in attitude one experiences after discovering it takes as little as 24 hours to get to the underwriting stage. And find out what its like to work with Endorphinators, a term used to describe the TMS loan team, those who provide such exceptional service that it releases a chemical in our clients' brain that causes extreme happiness. Experience the difference today.

This website is intended for the exclusive use of mortgage professionals only and is not for use by consumers. Information contained on this website is not considered an advertisement for consumer credit pursuant to Regulation Z, 12 C.F.R. 1026.24. Information, rates, and data are subject to change without notice. Other restrictions and limitations may apply. All Rights Reserved.

Site pending approval by the New York State Department of Financial Services.

See original here:

TMS - Wholesale

Help us bring the TMS Library/Media Center into the 21st Century for the 2018/19 School Year. A fundraiser has been createdon DonorsChoose.org posting a supply list of items that will be used in the new Makerspace Section of our library.

What is a Makerspace? It's an area that offers librarypatrons an opportunity to create intellectual and physical materials using resources such as computers, 3-D printers, audio and video capture and editing tools, and traditional arts and crafts supplies.

To make a donation, visit DonorsChoose.org.

Give to our library by May 11, 2018, and your donation will be doubled thanks to Ripple. Just enter the code RIPPLE during checkout and you'll be matched dollar for dollar (up to $50).

In return, you'll get awesome photos of your gift in action and our heartfelt thanks. Please feel free to pass this information along should you know anyone who may want to support our library.

Thank you, in advance, for your support in helping us create this new area of the library for our students.

See the article here:

Temecula Middle School - Official Site

TMS Engineering, Inc. is committed to providing the highest quality engineering and consulting services available to our clients while meeting schedule and budget requirements. Through our almost 30 year history, we have successfully upheld this commitment to our clients.

TMS has developed a philosophy and approach to engineering and design that we believe is the most efficient and cost effective for the client. In an effort to make the project a success, TMS makes every effort to understand the project objectives, not simply the engineering objectives. With this information, we can make the most informed and smart decisions during the design phase that will promote a successful project, not just a good engineering package.

Whether working in the preliminary phases of a project such as project scope and cost estimate development, or in the detail design phase, or in the execution phase of the project providing scheduling and planning, project management, or construction management, the staff at TMS Engineering has proven to add value with our practical project approach and hands on philosophy for engineering and consulting.

First and foremost, our emphasis is on quality of service. For large projects or small, TMS Engineering will constantly strive to achieve our ultimate goal:

Follow this link:

TMS Engineering - Home

Dr. Rao has over 20 years of experience treating major depressive disorder. The majority of his patients are people who have had depression for many years, if not for their whole life. Their depression has been recurrent, meaning that it keeps coming back despite treatment; or chronic, meaning that theyve experienced some level of depression, even low-grade baseline depression, that has never lifted; or they are people who say theyve been depressed since their teenage years. The traditional treatment for depression has been psychotherapy, the most effective of which is cognitive behavioral therapy. There are some patients who have great results with this treatment, but not everybody. The second type of treatment for depression is antidepressant medication. Similarly, many patients have great success with this type of treatment but we know from experience that about 50-60% have either an inadequate response or no response at all.

Dr. Rao has expertise in treating recurrent or chronic depression which has not responded to these ordinary treatments. Using new protocols for treating depression with antidepressants and TMS, our patients have a greater-than 60% rate of recovery, meaning full remission of their depressive symptoms. In addition, another 20-30% improve from severe or very severe levels of depression to the mild range with only residual symptoms remaining.

Dr. Rao offers comprehensive evaluation and treatment of clinical depression. Evaluations include complete psychiatric, medical and neurologic histories; medical and neurological examination; and state-of-the-art laboratory testing including genetic testing. Genetic testing can indicate why a patient has not responded to an antidepressant and can suggest what other types of antidepressants the patient might respond to.

TMS is the newest modality available to combat clinical depression. FDA guidelines indicate that TMS therapy is indicated for depressed patients who have undergone a course of psychotherapy and/or a course of 1 or more antidepressants that failed to eliminate the depressive episode. TMS is not a treatment of last resort, but rather a mainstream treatment that can be used routinely along with psychotherapy and medication.

More importantly, TMS has become an important or essential component of treatment of recurrent or chronic depression. Frequently patients who have had only a partial response to antidepressants achieve significant improvement, if not recovery, from depression.

The best candidate for TMS is a patient with clinical depression that has not had a satisfactory response to antidepressants; and/or has not improved with psychotherapy; and/or has experienced intolerable side effects.Mission Statement. The purpose of this Center and its sister practice is to provide outstanding psychiatric care based on the most recent advances in the field, including advances in psychotherapy, psychopharmacology and neuroscience.

See original here:

TMS Therapy Center of Tulsa - Cutting Edge Depression ...

Message from the TMS Management Team,

Today, Technical Mechanical Services (TMS) has long-term partnerships with end-users involved in construction & mining industries all over the world:

Our goal is a to be a worldwide supply chain provider proposing secured intelligent and alternative 360 solutions to our customers, and being recognised as excellent in the eyes of the customers, employees and the other important stakeholders of the Organisation.

With its headquarters and central warehouse in Lige, Belgium the location is the perfect choice; nearly all the major brands have substantial facilities in the region. The Organization is in partnership with dedicated freight forwarders and therefore is proud to have the capacity to offer multiple shipping methods. We understand our role within the supply chain considerations of our customers.

The organisation does not have an unwieldy hierarchy, but a dynamic corporate culture that represents a no-nonsense approach and efficiency. The level corporate culture leads to smooth communication and a quick decision-making process. At the heart of our corporate culture is our professionalism. In all our strategic development choices, and in the course of our everyday business activities, we are guided by this professionalism and by our entrepreneurial spirit. This is our foremost competitive advantage.

We are driven by the target of creating sustainable value for all its stakeholders. What sets us apart is our ability to develop and maintain mutually beneficial long-term business relationships. With the support of the whole TMS team, we hereby undertake to fulfil the mission of the company and help it realize its vision.

To realize our vision for the future, we need to strive for excellence in everything we do. In a highly competitive market, innovation in the services proposed must be a constant concern. We hereby undertake to encourage the creativity of our staff and the development of their skills by means of appropriate training.

Our excellent reputation is our most important Companys fundamental intangible resource, which represents an element of inward attraction for the best human resources who are interested in operating with our Company. Moreover, good reputation is an element which favours the relationships with business, entrepreneurial and financial partners

The Organization is committed to guaranteeing its Customers satisfaction. It is committed to building true and collaborative relations with them, and sets itself a reliable, qualified and trustworthy partner.

Although our business networks span the globe and our customer base spreads across all 5 continents, our business is tailored to the local needs of ours customers business. Each country has a dedicated team to meet with and support clients.

The TMS Management Team

Services & Products to meet your needs

Continue reading here:

TMS Worldwide A belgian company operating worldwide!

Help us bring the TMS Library/Media Center into the 21st Century for the 2018/19 School Year. A fundraiser has been createdon DonorsChoose.org posting a supply list of items that will be used in the new Makerspace Section of our library.

What is a Makerspace? It's an area that offers librarypatrons an opportunity to create intellectual and physical materials using resources such as computers, 3-D printers, audio and video capture and editing tools, and traditional arts and crafts supplies.

To make a donation, visit DonorsChoose.org.

Give to our library by May 11, 2018, and your donation will be doubled thanks to Ripple. Just enter the code RIPPLE during checkout and you'll be matched dollar for dollar (up to $50).

In return, you'll get awesome photos of your gift in action and our heartfelt thanks. Please feel free to pass this information along should you know anyone who may want to support our library.

Thank you, in advance, for your support in helping us create this new area of the library for our students.

See the original post:

Temecula Middle School: Home Page

Talk About Oversize Load

TMS Delivery, Inc. is a trucking and freight brokerage company dedicated to providing our customers with the transportation services they need with the timeliness they have come to expect. USDOT #687351

Remember at TMS Delivery, one call solves all your transportation needs!

This new service gives our customers a "one call solution" to their transportation requirements. This new services provides:

Click here for our Broker Pack.

Remember at TMS Delivery, one call solves all your transportation needs!

Coverage, Coverage, Coverage

Tyler area Locals Love Us for FIVE years in a ROW! Our service speaks for itself! Thank you Tyler, Texas for voting TMS Delivery #1 in the trucking industry for East Texas!

Click hereto read about TMS Delivery, Inc.'s Prophesy Dispatch User Success Story.TMS Delivery is EXPANDING! We are opening a location in HOUSTON, TEXAS. This location includes vans, flatbeds and more. Give us a call! We are a ONE CALL SOLUTION to all your trucking needs!

Excerpt from:

TMS Delivery | Freight Transportation Services, Trucking ...

Overview

Transcranial magnetic stimulation (TMS) is a noninvasive procedure that uses magnetic fields to stimulate nerve cells in the brain to improve symptoms of depression. TMS is typically used when other depression treatments haven't been effective.

During a TMS session, an electromagnetic coil is placed against your scalp near your forehead. The electromagnet painlessly delivers a magnetic pulse that stimulates nerve cells in the region of your brain involved in mood control and depression. And it may activate regions of the brain that have decreased activity in people with depression.

Though the biology of why rTMS works isn't completely understood, the stimulation appears to affect how this part of the brain is working, which in turn seems to ease depression symptoms and improve mood.

Treatment for depression involves delivering repetitive magnetic pulses, so it's called repetitive TMS or rTMS.

Mayo Clinic's approach

Depression is a treatable condition, but for some people, standard treatments aren't effective. Repetitive transcranial magnetic stimulation (rTMS) is typically used when standard treatments such as medications and talk therapy (psychotherapy) don't work.

Repetitive transcranial magnetic stimulation (rTMS) is a noninvasive form of brain stimulation used for depression. Unlike vagus nerve stimulation or deep brain stimulation, rTMS does not require surgery or implantation of electrodes. And, unlike electroconvulsive therapy (ECT), rTMS doesn't cause seizures or require sedation with anesthesia.

Generally, rTMS is considered safe and well-tolerated. However, it can cause some side effects.

Side effects are generally mild to moderate and improve shortly after an individual session and decrease over time with additional sessions. They may include:

Serious side effects are rare. They may include:

More study is needed to determine whether rTMS may have any long-term side effects.

Before having repetitive transcranial magnetic stimulation (rTMS), you may need a:

Tell your doctor or mental health provider if:

Repetitive TMS isn't invasive, doesn't require anesthesia and can be performed in a doctor's office. You don't need to arrange for someone to drive you home after treatment unless, for the first treatment, you prefer a driver until you get a sense of how you'll feel afterward.

Before considering treatment, check with your health insurance company to see whether rTMS is covered. Your policy may not cover it.

Repetitive transcranial magnetic stimulation (rTMS) is usually done on an outpatient basis in a doctor's office or clinic. It requires a series of treatment sessions to be effective. Generally, sessions are carried out daily, five times a week for four to six weeks.

Before treatment begins, your doctor will need to identify the best place to put the magnets on your head and the best dose of magnetic energy for you. Your first appointment typically lasts about 60 minutes.

Most likely, during your first appointment:

Once the coil placement and dose are identified, you're ready to begin. Here's what to expect during each treatment:

You can return to your normal daily activities after your treatment. Typically, between treatments, you can expect to work and drive.

There are different ways to perform the procedure. Techniques may change as experts learn more about the most effective ways to perform treatments.

If repetitive transcranial magnetic stimulation (rTMS) works for you, your depression symptoms may improve or go away completely. Symptom relief may take a few weeks of treatment.

Repetitive TMS may be less likely to work if:

The effectiveness of rTMS may improve as researchers learn more about techniques, the number of stimulations required and the best sites on the brain to stimulate.

It's not yet known if maintenance rTMS sessions will benefit your depression. This involves continuing treatment when you are symptom-free with the hope that it will prevent the return of symptoms. Most insurance companies don't cover maintenance rTMS.

However, if your depression improves with rTMS, and then later you have another episode of symptoms, your rTMS treatment can be repeated. This is called re-induction. Some insurance companies will cover re-induction.

If your symptoms improve with rTMS, discuss ongoing or maintenance treatment options for your depression with your doctor.

Explore Mayo Clinic studies testing new treatments, interventions and tests as a means to prevent, detect, treat or manage this disease.

Dec. 29, 2017

More:

Transcranial magnetic stimulation - About - Mayo Clinic

Edap Tms SA (EDAP) shares have seen their Schaff Trend Cycle gradually downtrendthis week over the past fewsessions. While this indicates negativeprice momentum, it also suggests that if the reading moves into oversold territory (STC of 30), thenthe liklihood of a reversal greatly increases. Investors will be watching very closely over the next few days to see if the trend contiunes or reverses.

The Schaff Trend Cycle (STC) indicator combines the common indicators of MACD & Stochastic. The benefit of the Schaff Trend Cycle is that it is meant to be quicker than the standard macd and stochastic signals. The indicator uses similar methods to a MACD i.e uses exponetial moving averages but applies a cycle factor to them. Then the price is smoothed using a mofidied Wilders smoothing algorithm. The Schaff Trend Cycle indicator fluctuates between 0 and 100. Readings below 20 are considered oversold while readings above 80 are considered overbought. The STCindicator fluctuates between 0 and 100. Readings below 20 are considered oversold while readings above 80 are considered overbought.

Active investors are typically interested in the factors that drive stock price movements. Buying an individual stock means that you own a piece of the company. The hope is that the company does very well and becomes highly profitable. A profitable company may decide to do various things with the profits. They may reinvest profits back into the business, or they may choose to pay shareholders dividends from those earnings. Sometimes stocks may eventually become undervalued or overvalued. Spotting these trends may lead to further examination or the underlying fundamentals of the company. A company that continues to disappoint on the earnings front may have some issues that need to be addressed. It is highly important to make sure all the research is done on a stock, especially if the investor is heavily weighted on the name. Sometimes earnings reports may be good, but the stock price does not reflect that. Having a good understanding of the entire picture may help investors better travel the winding stock market road.

Checking on some other popular technical levels, Edap Tms SA (EDAP) has a 14-day Commodity Channel Index (CCI) of -17.91. The CCI technical indicator can be employed to help figure out if a stock is entering overbought or oversold territory. CCI may also be used to help discover divergences that may signal reversal moves. A CCI closer to +100 may provide an overbought signal, and a CCI near -100 may provide an oversold signal.

Tracking other technical indicators, the 14-day RSI is presently standing at 37.05, the 7-day sits at 37.85, and the 3-day is resting at 41.71 for Edap Tms SA (EDAP). The Relative Strength Index (RSI) is a highly popular technical indicator. The RSI is computed base on the speed and direction of a stocks price movement. The RSI is considered to be an internal strength indicator, not to be confused with relative strength which is compared to other stocks and indices. The RSI value will always move between 0 and 100. One of the most popular time frames using RSI is the 14-day.

Moving averages have the ability to be used as a powerful indicator for technical stock analysis. Following multiple time frames using moving averages can help investors figure out where the stock has been and help determine where it may be possibly going. The simple moving average is a mathematical calculation that takes the average price (mean) for a given amount of time. Currently, the 7-day moving average is sitting at 2.67.

Lets take a further look at the Average Directional Index or ADX. The ADX measures the strength or weakness of a particular trend. Investors and traders may be looking to figure out if a stock is trending before employing a specific trading strategy. The ADX is typically used along with the Plus Directional Indicator (+DI) and Minus Directional Indicator (-DI) which point to the direction of the trend. The 14-day ADX for Edap Tms SA (EDAP) is currently at 23.41. In general, and ADX value from 0-25 would represent an absent or weak trend. A value of 25-50 would support a strong trend. A value of 50-75 would signify a very strong trend, and a value of 75-100 would point to an extremely strong trend.

Read the rest here:

What is the Schaff Indicator Suggesting For Edap Tms SA (EDAP)? - Morgan Research

August 24, 2017 16:20 ET | Source: EDAP TMS SA

LYON, France, August 24, 2017 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced that Marc Oczachowski, Chief Executive Officer, will present at the 19th Annual Rodman & Renshaw Global Investment Conference to be held September 10-12, 2017 at the Lotte New York Palace Hotel, New York, New York. EDAP-TMS' presentation will take place Monday, September 11th, 2017 at 3:00pm Eastern Time. A live broadcast of the conference presentation will be available. To access the broadcast, go to the "Investor Relations" section of the Company's website at http://www.edap-tms.net. A replay of the conference presentation will also be available.

About EDAP TMS SA

EDAP TMS SA markets today Ablatherm for high-intensity focused ultrasound (HIFU) for prostate tissue ablation in the U.S. and for treatment of localized prostate cancer in the rest of the world. HIFU treatment is shown to be a minimally invasive and effective option for prostatic tissue ablation with a low occurrence of side effects. Ablatherm-HIFU is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option, or for patients who failed radiotherapy treatment. Ablatherm-HIFU is approved for commercial distribution in Europe and some other countries including Mexico and Canada, and has received 510(k) clearance by the U.S. FDA. Ablatherm Fusion is not FDA cleared yet. The Company also markets an innovative robot-assisted HIFU device, the Focal One, dedicated to focal therapy of prostate cancer. Focal One is CE marked but is not FDA cleared. The Company also develops its HIFU technology for the potential treatment of certain other types of tumors. EDAP TMS SA also produces and distributes medical equipment (the Sonolith lithotripters' range) for the treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL) in most countries including Canada and the U.S. For more information on the Company, please visithttp://www.edap-tms.com, andhttp://www.hifu-prostate.com.

Forward-Looking Statements

In addition to historical information, this press release may contain forward-looking statements. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties, including matters not yet known to us or not currently considered material by us, and there can be no assurance that anticipated events will occur or that the objectives set out will actually be achieved. Important factors that could cause actual results to differ materially from the results anticipated in the forward-looking statements include, among others, the clinical status and market acceptance of our HIFU devices and the continued market potential for our lithotripsy device. Factors that may cause such a difference also may include, but are not limited to, those described in the Company's filings with the Securities and Exchange Commission and in particular, in the sections "Cautionary Statement on Forward-Looking Information" and "Risk Factors" in the Company's Annual Report on Form 20-F.

Investor Contact

CG CAPITAL Rich Cockrell 877.889.1972 investorrelations@cg.capital

Company Contact Blandine Confort Investor Relations / Legal Affairs EDAP TMS SA +33 4 72 15 31 50 bconfort@edap-tms.com

Vaulx-en-Velin, FRANCE

http://www.edap-tms.com

EDAP TMS SA Logo

LOGO URL | Copy the link below

Formats available:

Excerpt from:

EDAP TMS to Present at the 19th Annual Rodman & Renshaw Global Investment Conference - GlobeNewswire (press release)

CLAREMONT, Calif., Aug. 23, 2017 /PRNewswire/ --Achieve TMS, the largest and most experienced provider of deep Transcranial Magnetic Stimulation (dTMS) for the treatment of depression, will open a state-of-the-art center in Claremont, CA on September 1. This new center will enable local residents and students to benefit from the powerful and highly effective impact of dTMS technology, which is approved by the FDA and covered by every major health insurance company in the U.S.

"With 1 in 6 Americans suffering fromdepressionthere is a huge need for treatments that are proven to make a difference in the battle against this debilitating disease," said Manish Sheth, MD, PhD. "Deep Transcranial Magnetic Stimulation (TMS) is known to be an effective tool in the battle. Patients and their families are looking for an effective way to move away from depression into a place where lives are productive, balanced, healthy and well integrated. TMSis a vital tool that helps facilitate healing. We look forward to partnering with psychiatrists, psychologists and therapists in the Claremont area to expand access to this treatment option."

Deep TMS works by administering magnetic pulses through an H-coil on the scalp that is targeted to the mood center of the brain. The magnetic fields induce electrical currents that stimulate underactive neurons, helping to reset brain chemistry, resulting in improved sleep, concentration and overall mood. It is safe, non-invasive and highly effective for those who are treatment resistant and/or have experienced no relief from medication.

In more than 60 clinical studies globally, dTMS has consistently demonstrated statistically significant response and remission rates. The therapy is well tolerated by patients, causing no adverse effects. Treatment sessions are prescribed 5 days per week for 4-6 weeks, with each session lasting 20 minutes. There is no sedation involved, and no down time.

The new Achieve TMS Center in Claremont is located at 1490 Claremont Blvd. Suite 203.

Achieve TMS welcomes inquiries about the dTMS treatment and is scheduling complimentary consultations and appointments for Claremont at this time.

For more information please contact Achieve TMS at (877) 391-7019 or visit http://www.achievetms.com.

For media inquiries, please contact:

Laura Segall, Chief Marketing Officer

760-533-2784

172840@email4pr.com

View original content with multimedia:http://www.prnewswire.com/news-releases/landmark-tms-provider--achieve-tms--opening-in-claremont-ca-300507785.html

SOURCE AchieveTMS

http://www.achievetms.com

More here:

Landmark TMS Provider - Achieve TMS - Opening in Claremont, CA - PR Newswire (press release)

August 23, 2017 16:01 ET | Source: EDAP TMS SA

EDAP-TMS Reports Record Second Quarter and First Half 2017 Results

LYON, France, August 23, 2017 -- EDAP TMS SA (Nasdaq: EDAP), the global leader in therapeutic ultrasound, announced today financial results for the second quarter ended June 30, 2017, and provided an update on strategic and operational accomplishments.

"We are incredibly pleased to announce record second quarter revenue of 9.3 million", said Marc Oczachowski, EDAP's Chief Executive Officer. "Additionally, the 25% growth in HIFU revenues compared to the first quarter of 2017 shows a significant return from our increased sales and marketing efforts. We also submitted our 510(k) filing to the FDA for our novel Ablatherm Fusion device recently, and are working to file a new 510(k) application with the FDA for the Focal One device in the U.S. The addition of these HIFU devices to our U.S. marketing efforts, coupled with the active C-Code, should serve to help our customers service the widest possible range of patients."

Second Quarter 2017 Results

Total revenue for the second quarter 2017 was EUR 9.3 million (USD 10.4 million), compared to EUR 8.2 million (USD 9.2 million) for the second quarter of 2016, a 13.7% increase and the highest second quarter revenue in EDAP's history.

For the three months ended June 30, 2017, total revenue for the Lithotripsy division was EUR 6.4 million (USD 7.2 million), a 33.9% increase compared to EUR 4.8 million (USD 5.4 million) during the year-ago period. During the second quarter of 2017, EDAP sold 7 lithotripsy devices compared to 6 lithotripsy devices sold during the second quarter of 2016.

Total revenue in the HIFU business for the second quarter was EUR 2.9 million (USD 3.2 million) compared to EUR 3.4 million (USD 3.8 million) for the second quarter of 2016. During the second quarter of 2017, EDAP sold 1 Focal One and 2 Ablatherm HIFU devices compared to 1 Focal One and 3 Ablatherm devices during the second quarter of 2016.

Gross profit for the second quarter 2017 was EUR 4.0 million (USD 4.5 million), compared to EUR 3.5 million (USD 3.9 million) for the year-ago period. Gross profit margin on net sales expanded to 43.2% in the second quarter of 2017, compared to 42.2% in the prior year period, primarily due to increase in revenues.

Operating expenses for the second quarter of 2017 totaled EUR 4.4 million (USD 5.0 million) for the second quarter of 2017, compared to EUR 3.8 million (USD 4.3 million) for the same period in 2016. The increase reflects increased sales and marketing efforts associated with the expansion of the HIFU and UDS businesses.

Operating loss for the second quarter of 2017 was EUR 0.4 million (USD 0.5 million), compared to an operating loss of EUR 0.3 million (USD 0.4 million) in the second quarter of 2016.

Net loss for the second quarter of 2017 was EUR 1.7 million (USD 2.0 million), or loss of EUR 0.06 per diluted share, as compared to net income of EUR 2.5 million (USD 2.8 million), or earnings of EUR 0.09 per diluted share in the year-ago period. Net loss during the second quarter of 2017 included a non-cash interest expense of EUR 0.6 million (USD $0.6 million) to adjust the accounting fair value of the outstanding warrants.

First Six Months 2017 Results

Total revenue for the first half of 2017 was EUR 18.0 million (USD 19.7 million) - a new record level for the period, up 6.3% compared to EUR 16.9 million (USD 18.8 million) for the first half of 2016. For the six months ended June 30, 2017, total revenue for the Lithotripsy division was EUR 12.8 million (USD 14.0 million), an increase of 24.6% when compared to EUR 10.2 million (USD 11.4 million), during the year ago period. This increase was driven by growth in both the distribution business and lithotripsy device sales.

Total revenue in the HIFU division for the first six months 2017 was EUR 5.2 million (USD 5.7 million) compared to EUR 6.7 million (USD 7.4 million) for the six months ended June 30, 2016. This decrease was primarily due to slow U.S. sales of HIFU devices during the first half of the year, tempered by an increase in HIFU treatment driven revenues.

Gross profit for the first half of 2017 was EUR 7.6 million (USD 8.3 million) and gross profit margin was 42.1%, compared to 45.8% in the year ago period. The contraction in gross profit margin was primarily due to an unfavorable mix of HIFU and UDS segment revenues.

The Company recorded an operating loss for the first half of 2017 of EUR 0.8 million (USD 0.9 million), compared with an operating profit of EUR 0.4 million (USD 0.4 million) in the first six months of 2016.

Net loss for the first half of 2017 was EUR 0.1 million (USD 0.1 million), or EUR 0.00 per diluted share, as compared to a net income of EUR 3.9 million (USD 4.3 million), or EUR 0.14 per diluted share, in the first half of 2016. Net income for the first six months of 2017 included non-cash interest income of EUR 1.4 million (USD 1.5 million) to adjust the accounting fair value of the outstanding warrants

At June 30, 2017, cash and cash equivalents, including short-term treasury investments, were EUR 18.6 million (USD 21.2 million).

Conference Call

An accompanying conference call will be conducted by Philippe Chauveau, Chairman of the Board, Marc Oczachowski, Chief Executive Officer; and Francois Dietsch, Chief Financial Officer, to go over the results. The call will be held at 9:00 AM ET, on Thursday, August 24, 2017. Please refer to the information below for conference call dial-in information and webcast registration.

Conference Date:Thursday, August 24, 2017, 9:00 AM ET Conference dial-in:877-269-7756 International dial-in:201-689-7817 Conference Call Name:EDAP-TMS Second Quarter 2017 Results Conference Call Webcast Registration:Click Here

Following the live call, a replay will be available on the Company's website, http://www.edap-tms.com under "Investors Information."

About EDAP TMS SA

EDAP TMS SA markets today Ablatherm for high-intensity focused ultrasound (HIFU) for prostate tissue ablation in the U.S. and for treatment of localized prostate cancer in the rest of the world. HIFU treatment is shown to be a minimally invasive and effective option for prostatic tissue ablation with a low occurrence of side effects. Ablatherm-HIFU is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option, or for patients who failed radiotherapy treatment. Ablatherm-HIFU is approved for commercial distribution in Europe and some other countries including Mexico and Canada, and has received 510(k) clearance by the U.S. FDA. Ablatherm Fusion is not FDA cleared yet. The Company also markets an innovative robot-assisted HIFU device, the Focal One, dedicated to focal therapy of prostate cancer. Focal One is CE marked but is not FDA approved. The Company also develops its HIFU technology for the potential treatment of certain other types of tumors. EDAP TMS SA also produces and distributes medical equipment (the Sonolith lithotripters' range) for the treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL) in most countries including Canada and the U.S. For more information on the Company, please visit http://www.edap-tms.com, andhttp://www.hifu-planet.com.

Forward-Looking Statements

In addition to historical information, this press release may contain forward-looking statements. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties, including matters not yet known to us or not currently considered material by us, and there can be no assurance that anticipated events will occur or that the objectives set out will actually be achieved. Important factors that could cause actual results to differ materially from the results anticipated in the forward-looking statements include, among others, the clinical status and market acceptance of our HIFU devices and the continued market potential for our lithotripsy device. Factors that may cause such a difference also may include, but are not limited to, those described in the Company's filings with the Securities and Exchange Commission and in particular, in the sections "Cautionary Statement on Forward-Looking Information" and "Risk Factors" in the Company's Annual Report on Form 20-F.

EDAP TMS S.A. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) (Amounts in thousands of Euros and U.S. Dollars, except per share data)

Three Months Ended: Three Months Ended:

Net sales of RPP and Leases

1,304

1,316

1,458

1,474

2,037

1,611

NOTE: Translated for convenience of the reader to U.S. dollars at the 2017 average three months' noon buying rate of 1 Euro = 1.1181USD, and 2016 average three months' noon buying rate of 1 Euro = 1.1203 USD.

EDAP TMS S.A. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) (Amounts in thousands of Euros and U.S. Dollars, except per share data)

Six Months Ended: Six Months Ended:

Net sales of RPP and leases

2,599

2,578

2,844

2,865

3,879

3,078

4,244

3,421

NOTE: Translated for convenience of the reader to U.S. dollars at the 2017 average six months' noon buying rate of 1 Euro = 1.0942USD, and 2016 average six months' noon buying rate of 1 Euro = 1. 1116 USD.

EDAP TMS S.A. CONSOLIDATED BALANCE SHEETS HIGHLIGHTS (Amounts in thousands of Euros and U.S. Dollars)

NOTE: Translated for convenience of the reader to U.S. dollars at the noon buying rate of 1 Euro = 1.1412 USD, on June 30, 2017 and at the noon buying rate of 1 Euro = 1.0697 USD, on March 31, 2017.

EDAP TMS S.A. CONDENSED STATEMENTS OF OPERATIONS BY DIVISION SIX MONTHS ENDED JUNE 30, 2017 (Amounts in thousands of Euros)

HIFU Division

UDS Division

Corporate

Sales of goods

2,626

8,852

11,478

Research & Development

(1,211)

OPERATING PROFIT (LOSS)

(884)

804

(768)

(847)

Contact Blandine Confort Investor Relations / Legal Affairs EDAP TMS SA +33 4 72 15 31 72 bconfort@edap-tms.com

Investors Rich Cockrell CG CAPITAL 877.889.1972 investorrelations@cg.capital

Read more:

EDAP TMS Reports Record Second Quarter and First Half 2017 Results - GlobeNewswire (press release)

To celebrate TMSs 60th birthday, a match is being played (and commentated upon) in Leeds. Agnews team will take on Geoffrey Boycotts; with the two broadcasting greats represented by their respective on-field captains Phil Tufnell and Vaughan. I think I may have drawn the short straw with my captain, Agnew said with a smile.

TMS favourites will play, as well as celebrities including Jim Carter of Downton Abbey, sprinter Yohan Blake and McFly drummer Harry Judd (a good cricketer, according to Agnew).

They could have sold 10 times the tickets, Agnew said. The TMS mystique remains strong.

It is amazing how much this programme continues to appeal, Agnew said.

Our audience numbers go up and up.

It is a companion for people: most are listening in a confined space, car, headphones in the office, in bed. Often for seven hours a day, five days at a time. There is a feeling of camaraderie, that we are in it together.

For many, TMS has been there during good times and bad. Agnew himself experienced this recently.

My wife Emma has been diagnosed with breast cancer, he said. Because of the nature of the relationship we have with listeners, if I am not on it, people will ask wheres Aggers?

Read the rest here:

Like most families, Test Match Special has had some bitter rows - Telegraph.co.uk

Geoffrey Boycott chats to Jamacian sprinter Yohan Blake. Picture: Jonathan Gawthorpe

Published: 18:04 Thursday 24 August 2017

THE WEST Indies side that will step out against England at Headingley today has already taken some ribbing, but it was at a stadium two miles up the Otley Road this afternoon that the real comedians were to be found.

The BBCs Test Match Special, to celebrate its 60th anniversary, fielded two teams of jokers, retired cricketers and assorted pundits for a Twenty20 match on a Leeds University pitch at Weetwood that looked more village green than international stadium.

Geoffrey Boycott, 40 years to the month since scoring his 100th century in another Headingley Test, was one of the coaches, along with commentator Jonathan Agnew.

Boycott, these days a controversial summariser on the BBC radio warhorse, had said 24 hours earlier that this West Indies lot was the worst Test match team he had seen in more than 50 years of watching, playing and commentating.

Never one to mince his words, he appeared unrepentant as he strode onto what he described as a pockmarked pitch, beneath his customary straw Panama hat.

Instead, he offered some sage advise to his captain, Michael Vaughan. When the suns out and the pitch is dry, bat first in Yorkshire, he counselled.

Phil Tufnell, the opposing captain, was also not a stranger to the Yorkshire climate. You always come to Leeds and you always look up, he said.

The comedians taking to the crease included Andy Parsons, Dom Joly and Miles Jupp. They were joined by Made In Chelseas Jamie Laing, athlete Yohan Blake and Baroness Tanni Grey-Thompson.

The teams also included England cricket veterans Graeme Swann, Simon Hughes, Ebony Rainford Brent and Charlotte Edwards and BBC commentators Simon Mann and Alison Mitchell.

{* loginWidget *}

{* traditionalSignIn_emailAddress *} {* traditionalSignIn_password *}

Email Address {* traditionalSignIn_emailAddress *} Password {* traditionalSignIn_password *}

{* traditionalSignIn_emailAddress *} {* traditionalSignIn_password *}

{* traditionalRegistration_firstName *} {* traditionalRegistration_lastName *} {* traditionalRegistration_emailAddress *} {* traditionalRegistration_password *} {* traditionalRegistration_passwordConfirm *} {* traditionalRegistration_displayName *}

{* socialRegistration_firstName *} {* socialRegistration_lastName *} {* socialRegistration_emailAddress *} {* socialRegistration_displayName *}

{* socialRegistration_jpCommsOptIn *}

Registering with Yorkshire Post means you're ok with our terms and conditions.

{* socialRegistration_captcha *}

{* socialRegistration_firstName *} {* socialRegistration_lastName *} {* socialRegistration_emailAddress *} {* socialRegistration_displayName *}

{* socialRegistration_jpCommsOptIn *}

By registering you are agreeing to the Terms and Conditions of the website.

You're almost there.We've just sent a confirmation email to . Check it out to confirm your registration.

We are unable to send your welcome email at this time. Please try again later by clicking the resend welcome email link from your profile page.

{* traditionalSignIn_emailAddress *}

{* traditionalSignIn_emailAddress *}

{* newpassword *} {* newpasswordConfirm *}

{| foundExistingAccountText |}. Either connect these accounts, or create new one using a different email address.

{| existing_provider |}

{| existing_displayName |}

{| current_emailAddress |}

{| rendered_existing_provider_photo |}

Created at {| existing_createdDate |}

Email is already registered with OtherSite. You'll be able to use the same account on current Site. Alternatively, you can create a new account with another email address.

{* traditionalSignIn_emailAddress *} {* mergePassword *}

Enter your postcode so we can keep you up-to-date with the latest local news and exciting deals.

is already registered with . You will be able to use the same account on . Alternatively, you can create a new account with another email address.

Validating

Email address is required.

We have sent a confirmation email to . Please check your email and click on the link to activate your account.

We are unable to process your request at this time. Please try again later.

Congratulations, you've just sealed the deal! Sign in to your profile now to get started.

That's it, you're all done! Close this window to start browsing the site now or click here to go to your profile

Unfortunately that verification link has expired. To get a new one, just sign in to your profile now and resend the verification email.

Unfortunately that verification link has expired. To get a new one, just resend the verification email by going to your profile page.

Are you sure you want to remove this linked account?

See the rest here:

Boycott leads out jokers at TMS T20 Test in Leeds - Yorkshire Post

Transcranial Magnetic Stimulation (TMS)is a non-invasive treatment for depression offered at Trifecta Health Medical Center in Downtown Manhattan NYC.

Dr. Fruitman, M.D. has been successfully treating patients with TMS since 2010, and is an expert in treatment with TMS Therapy and psychopharmacology.

TMS Therapy is an FDA-cleared safe and effective non-drug depression treatment for patients who are not satisfied with the results of standard drug therapy. It can alleviate unwanted side effects commonly associated with antidepressants such as weight gain, sedation and sexual problems.

There is no need for anyone to go through his or her entire life suffering from depression.

Depression is a brain disease and too often its not treated by a specialist and can lead to devastating consequences.

Many patients are not aware of all the tools available for treatment including non-drug treatment options. We have a proven advanced technology, TMS Therapy that may get patients well in just a few weeks and does not have the side effects of medications.

For patients who have tried antidepressant medications with no symptom improvement, there is TMS therapy. NeuroStar TMS is a safe, effective, treatment options for adults who suffer from major depression. Remission from depression is possible with NeuroStar TMS therapy available at Trifecta Health Medical Center.

As a pioneer of TMS Treatment in New York City, Dr. Fruitman artfully integrates his skills as apsychopharmacologist and psychotherapist, with innovative technology of TMS.

TMS uses magnetic stimulation of the brain to help control mood in adults with major depression. The procedure was approved by the U.S. Food and Drug Administration in October 2008 after more than 10 years of clinical investigation in patients who failed to achieve satisfactory improvement from one course of Pharmacotherapy (medication). For this reason, TMS is particularly helpful for people who have not experienced significant relief from antidepressant medications or who have difficulty with their side effects.

TMS uses focused magnetic pulses to non-invasively stimulate the brain in the prefrontal cortex (the region of the brain associated with mood regulation).

During a TMS treatment NYC, a clinician gently places a magnetic coil against one side of a patients head.

The magnetic fields penetrate approximately two to three centimeters beneath the scull directly into the brain to produce electrical currents. These currents activate cells within the brain that are thought to release neurotransmitters, which play a role in mood regulation. Since depression is believed to be caused by an imbalance of chemicals in the brain, TMS helps restore balance and relieve the symptoms of depression.

Through a treatment coil, the NeuroStar TMS Therapy system generates highly concentrated, magnetic fields which turn on and off very rapidly. These magnetic fields are the same type and strength as those produced by a magnetic resonance imaging (MRI) machine.

This procedure is completely painless and non-invasive, performed similarly to an MRI scan of the brain.Each treatment session takes about 30 minutes to perform, and patients can resume their regular activities immediately after each TMS session.To achieve effective results, patients will need to undergo multiple visits each week for three to six weeks, depending on their individual condition.

TMS requires no anesthesia or sedation and patients are awake and alert during the procedure. Because no medications are administered, there are no systemic side effects or cognitive after-effects (memory loss and ability to concentrate); therefore, patients can return immediately toregular activity.

During a TMS therapy session at Trifecta Health, the patient sits in a comfortable reclining chair similar to that found in a dentists office. A headset is applied to deliver the magnetic stimulation. Ear plugs are provided to decrease the loud clicks associated with each magnetic pulse and the patient is given the option of watching TV. During the procedure, the patient is monitored continuously to ensure correct positioning and comfort level.

Trifecta Health in Downtown New York pioneered the technique of engaging the patient in Cognitive/Supportive Psychotherapy during the course of TMS treatments, administered by a Licensed Mental Health Counselor.

More than 10,000 TMS treatments were safely performed during clinical trials. Patients reported no side effects like those associated with antidepressant medication (weight gain, dry mouth, drowsiness, sexual side effects, etc.), and no cognitive side effects. Scalp discomfort during the procedure is the most common side effect.

TMS therapy should not be used for patients with implanted metallic devices that include metal plates in the skull or aneurysm coils, clips or stents. Special precautions are recommended for individuals with implants, such as pacemakers and implantable cardioverter defibrillators.

Both private and public insurers are determining eligibility for TMS therapy on an individual basis. However, until TMS is accepted more widely as a medically necessary treatment, insurance coverage will most likely not be authorized. Patients should work directly with their insurers to determine coverage. Patients can then work with a Patient Account representative to arrange payment schedules and to obtain assistance in applying for reimbursement of out-of-pocket expenses from their insurers.

Trifecta Health teamed up with Neuronetics, the manufacturer of TMS equipment, to work with patients insurance carriers to maximize insurance reimbursement for out-of-pocket expenses associated with TMS.

AtTrifecta Health treatments for depression are offered with great care and expertise, and as an innovative and highly attentive medical center, Trifecta offers the latest treatments for depression in New York City.

See original here:

TMS Therapy NYC, Depression Treatment in New York ...